Table 1.

Clinical trials of PROTACs compounds, disease or tumor for which they are being tested, and clinical phase

NCT	Compound (Target)	Conditions	Phase
NCT03888612	ARV-110 (AR)	Prostate cancer metastatic	I/II
NCT04072952	ARV-471 (ER)	Breast cancer	I/II
NCT05067140	ARV-766 (AR)	Prostate cancer metastatic	I
NCT04428788	CC-94676 (AR)	Prostatic neoplasms	I
NCT04886622	DT2216 (BCL-xL)	Solid tumor/Hematologic malignancy	I
NCT04772885	KT-474 (IRAK4)	Healthy volunteer/atopic dermatitis/hidradenitis suppurativa	I
NCT04830137	NX-2127 (BTK)	Hematologic malignancy	I
NCT03891953	DKY709 (IKZF2)	Non-small-cell lung carcinoma/Melanoma/Nasopharyngeal carcinoma/Colorectal cancer/TNBC	I